Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Winscott

Interventional Cardiology Jackson, MS Medical Doctor

NPI 1124113667 CMS profile 96812

2500 N State Street, Dept Of Medicine Division Of Cardiology, Jackson, MS 39216

Open in the dashboard

General payments

$482,361

1,276 records reported · program years 2019–2025

Research payments

$4,275

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Winscott of Jackson, MS is reported in the CMS Open Payments database as having received $482,361 across 1,276 general payments and $4,275 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $115,881 281
2024 General $80,000 194
2024 Research $3,800 1
2023 General $85,807 191
2023 Research $475 2
2022 General $69,883 197
2021 General $29,550 135
2020 General $29,782 98
2019 General $71,459 180

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Winscott
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to John Winscott were reported at $115,881. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year John Winscott Interventional Cardiology median Middle half National median
2019 $71,459 $1,097 $329–$3,048 $163
2020 $29,782 $473 $161–$1,480 $114
2021 $29,550 $677 $233–$1,827 $132
2022 $69,883 $978 $333–$2,724 $149
2023 $85,807 $1,136 $382–$2,986 $160
2024 $80,000 $1,181 $395–$3,326 $164
2025 $115,881 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $295,365 677 payments
  2. Medtronic Vascular, Inc. $98,509 188 payments
  3. Shockwave Medical, Inc $74,069 91 payments
  4. Abiomed $4,907 164 payments
  5. Inari Medical, Inc. $2,690 36 payments
  6. Endologix, Inc. $1,149 5 payments
  7. Penumbra, Inc. $830 8 payments
  8. W. L. Gore & Associates, Inc. $591 2 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $522 13 payments
  10. Stryker Corporation $437 8 payments
  11. Other $3,292 84 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $267,138 60 payments
  2. Travel and Lodging $84,801 226 payments
  3. Consulting Fee $66,805 35 payments
  4. Food and Beverage $44,368 949 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $19,250 6 payments
Products named General payments · program years 2019–2025
  1. HawkOne Directional Atherectomy Devices $171,141 250 payments
  2. TurboHawk Directional Atherectomy Devices $58,155 184 payments
  3. IN.PACT Admiral Drug-Coated Balloons $45,171 115 payments
  4. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $44,595 56 payments
  5. IN.PACT Admiral Drug-Coated Balloons $42,503 53 payments
  6. TurboHawk Directional Atherectomy Devices $39,278 25 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $29,210 33 payments
  8. HawkOne Directional Atherectomy Devices $12,884 71 payments
  9. FlowMet $7,212 6 payments
  10. Impella $4,850 163 payments
  11. Other $25,061 330 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $4,275 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,170

Median for Interventional Cardiology: 2,236

Drug cost

$150,636

Median for Interventional Cardiology: $380,412

Branded share of claims

34%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 40 $42,801
Eliquis Apixaban Brand 35 $34,573
Jardiance Empagliflozin Brand 30 $27,496
Farxiga Dapagliflozin Propanediol Brand 15 $18,609
Repatha Sureclick Evolocumab Brand 12 $9,543
Brilinta Ticagrelor Brand 16 $7,533
Clopidogrel Clopidogrel Bisulfate Brand 173 $1,656
Metoprolol Succinate Generic 113 $1,489
Nifedipine Er Nifedipine Brand 13 $1,474
Atorvastatin Calcium Generic 130 $1,067

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$105,116

Medicare's payments for the services billed

Medicare patients

404

Average age 74

Services billed

1,127

187 women, 217 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 59%
Arthritis 54%
Diabetes 53%
Chronic kidney disease 43%
Heart failure 39%
Atrial fibrillation 27%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$95 30 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,279 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record